Promising breast cancer drug (Lapatinib) enters final phase

In stage one clinical trials done at Duke University, almost half of the women with advanced breast tumors of this type (Her2) who were given Lapatinib had their disease stabilize or had their tumor shrink in the first eight weeks of the study. http://news-info.wustl.edu/news/page/normal/3564.html

Lapatinib is also known as GW572016. If anyone is interested in joining the trials. Go to our Clinical Trial News page..It is listed under GSK.

Regards
Joe